Research Topics
Genomes and GenesSpecies | Nadia HarbeckSummaryAffiliation: University of Cologne Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×DocetaxelEva J Kantelhardt
Klinik und Poliklinik für Gynäkologie, Martin Luther Universitat, Halle Saale, Germany
BMC Cancer 11:140. 2011..High-risk node-negative patients should receive chemotherapy. Anthracycline-based regimens are accepted as a standard, the additional benefit of taxanes remains an open question...- CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patientsDimo Dietrich
Epigenomics AG, Berlin, Germany
BMC Cancer 10:247. 2010..In this study, the DNA methylation status of 202 candidate loci was screened to identify those loci that may predict outcome in LNP/estrogen receptor-positive (ER+) breast cancer patients with adjuvant anthracycline-based chemotherapy... 
Cardiovascular complications of conventional and targeted adjuvant breast cancer therapyN Harbeck
Department of Oncology, Breast Center, Department of Obstetrics and Gynecology, University of Cologne, Cologne, Germany
Ann Oncol 22:1250-8. 2011..Since adjuvant therapy for BC is potentially curative, emphasis must be placed on finding treatments combining maximum efficacy with the minimum of long-term side-effects in order to achieve survival with preserved quality of life...- A new look at node-negative breast cancerNadia Harbeck
Breast Center, University of Cologne, Cologne, Germany
Oncologist 15:29-38. 2010..Node-negative breast cancer does not automatically suggest a good prognosis, or the preclusion of chemotherapy benefits, and additional biomarkers are needed to help identify patients who do benefit from chemotherapy... - Personalized treatment of early-stage breast cancer: present concepts and future directionsNadia Harbeck
Breast Center, Department of Gynecology and Obstetrics, University Hospital Köln, Cologne, Germany
Cancer Treat Rev 36:584-94. 2010..It will also highlight how carefully molecular tests need to be methodologically and clinically validated before they can be applied for clinical decision making... - A new look at node-negative breast cancerNadia Harbeck
Breast Center, University of Cologne, Cologne, Germany
Oncologist 16:51-60. 2011..Node-negative breast cancer does not automatically suggest a good prognosis, or the preclusion of chemotherapy benefits, and additional biomarkers are needed to help identify patients who do benefit from chemotherapy... 
Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancerNadia Harbeck
Department of Obstetrics and Gynecology, Technical University of Munich, Germany
Clin Breast Cancer 5:348-52. 2004....- Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patientsJulia Dorn
Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
Clin Cancer Res 13:1742-8. 2007.... - Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III studyVolker Moebus
Department of Gynecology and Obstetrics, Klinikum Frankfurt Hoechst, Academic Hospital of Goethe University Frankfurt, Gotenstrasse 6 8, D 65929, Frankfurt, Germany
J Clin Oncol 28:2874-80. 2010..We compared intense dose-dense (IDD) adjuvant chemotherapy with conventionally scheduled adjuvant chemotherapy in patients with high-risk primary breast cancer... - Side-effects of pre-operative epirubicin-paclitaxel therapy in primary breast cancer associated with tumor biologyMathias Warm
Department of Senology, University of Cologne, Cologne, Germany
Anticancer Res 29:2675-80. 2009..The objective of this analysis is to identify relationships between side-effects, tumor biological factors and response to pre-operative epirubicin and paclitaxel therapy in primary breast cancer... - Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424)Nadia Harbeck
Department of Obstetrics and Gynecology, Technical University, D 81675 Munich, Germany
Cancer Res 62:4617-22. 2002.... - 3D breast ultrasound: a significant predictor in breast cancer reduction under pre-operative chemotherapyMathias Warm
Department of Senology, University of Cologne, Cologne, Germany
Anticancer Res 31:4039-42. 2011..The objective was the investigation of a possible predictive quantitative impact of initial tumor sphericity, measured by 3D sonography, on response to pre-operative chemotherapy... - Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancerMathias Warm
Department of Senology, University of Cologne, Germany
Onkologie 30:436-41. 2007..This is a retrospective cohort study on the safety and efficacy profiles of weekly docetaxel at varying doses in patients with pretreated metastatic breast cancer... - Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy conceptsNadia Harbeck
Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
Clin Breast Cancer 3:196-200. 2002..Thus, combined determination of the invasion factors uPA and PAI-1 supports risk-adapted individualized therapeutic strategies in patients with primary breast cancer, particularly in those with node-negative breast cancer... - Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trialsSibylle Loibl
Department of Obstetrics and Gynecology, German Breast Group, Neu Isenburg, Germany
Breast Cancer Res 10:R77. 2008..Furthermore, most physicians tend towards therapy regimens without the use of dose-dense, highly active taxane-based treatments because of a lack of data regarding toxicities of these compounds in older patients... - Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancerMathias Warm
Department of Senology, University of Cologne, Germany
Anticancer Res 27:1031-8. 2007.... - Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancerNadia Harbeck
Department of Obstetrics and Gynecology, Technical University of Munich, Germany
Thromb Haemost 91:450-6. 2004.... - Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithmsNadia Harbeck
Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
Crit Rev Clin Lab Sci 44:179-201. 2007..This concept could be useful in assessing and maximizing the performance of risk assessment and the quality of therapeutic indications... - Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patientsMathias Warm
Breast Center, University of Cologne, Kerpener Strasse 62, 50924 Cologne, Germany
Breast Cancer Res Treat 125:127-36. 2011.... - Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinomaJulia Dorn
Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, D-81675 Munich, Germany, and Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
Biol Chem 387:1121-8. 2006..These results support the notion that several tissue kallikreins are co-expressed in ovarian cancer patients, substantiating the existence of a steroid hormone-driven tissue kallikrein cascade in this disease... - Health-related quality of life in male breast cancer patientsChristoph Kowalski
Institute for Medical Sociology, Health Services Research and Rehabilitation Science, Faculty of Human Science and Faculty of Medicine, University of Cologne, Cologne, Germany
Breast Cancer Res Treat 133:753-7. 2012..Future research needs to assess HRQoL with cancer-specific questionnaires and longitudinal designs also focussing on male patients in breast centres... - Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapyOleg Gluz
Breast Center, University of Cologne, Kerpener Strasse 34, 50931 Cologne, Germany
J Clin Oncol 27:6144-51. 2009.... - Postoperative sense of well-being and quality of life in breast cancer patients do not depend on type of primary surgeryMathias Warm
Department of Senology, University of Cologne, Germany
Onkologie 31:99-104. 2008..3 types of surgery are compared: breast-conserving surgery; modified radical mastectomy with or without primary reconstruction... - FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancerChristoph Thussbas
Department of Obstetrics and Gynecology, Institute of Pathology, and Institute for Medical Statistics and Epidemiology, Technical University of Munich, Munich, Germany
J Clin Oncol 24:3747-55. 2006..5 months)... - Antibody therapy for breast cancerAmina Willems
Department of Obstetrics and Gynecology, Technical University of Munich, Germany
Anticancer Res 25:1483-9. 2005..It binds to a different epitope on HER2/neu than trastuzumab and inhibits heterodimerization with other HER receptors. Phase I data showed that 2C4 is well tolerated and clinically active... - European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkersManfred Schmitt
Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, Germany
Eur J Cancer 43:835-44. 2007..The resulting tissue cell debris sediment is a rich source of genomic DNA... - Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarkerAriane Sadr-Nabavi
Department of Obstetrics and Gynecology, Technische Universitaet Muenchen, Munich, Germany
Int J Cancer 124:1727-35. 2009..Furthermore, these data point towards a possible predictive impact of EFEMP1 expression in primary breast cancer... - Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combinationNadia Harbeck
Clinical Research Group, Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
J Clin Oncol 20:1000-7. 2002..The improvement in clinical risk assessment gained by combining these factors is evaluated here... - Optimized pro-active management of anemia by Epoetin alpha in pre-operative chemotherapy for primary breast cancerMathias Warm
Department of Senology, University of Kologne, Germany
Oncol Rep 21:777-85. 2009.... - Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and TManfred Schmitt
Clinical Research Unit, Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaninger Strasse 22, D 81675 Munich, Germany
Int J Oncol 25:1397-406. 2004..With this approach, a major step forward in the knowledge and understanding of the biological role and the clinical utility of tumor-associated biomarkers would be anticipated... - Associations between hospital and patient characteristics and breast cancer patients' satisfaction with nursing staffChristoph Kowalski
Institute for Medical Sociology, Health Services Research and Rehabilitation Science, Faculty of Human Science and Faculty of Medicine, University of Cologne, Germany
Cancer Nurs 35:221-8. 2012..Only a few studies have investigated the association between hospital characteristics and breast cancer patients' satisfaction with nursing staff... - Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individualsKatharina Seck
Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
Clin Cancer Res 11:5886-92. 2005..The results reflect the genetic and enzymatic variability of DPD in the population and may contribute to further insight into the pharmacogenetic disorder of DPD deficiency... - Angiogenesis inhibitors in the management of breast cancerVerena Bossung
Breast Center, Department of Obstetrics and Gynecology, University Hospital of Cologne, Cologne, Germany
Curr Opin Obstet Gynecol 22:79-86. 2010..This review highlights therapeutic agents from recent breast cancer trials showing the greatest potential for further clinical use in the near future... - Immunohistochemical demonstration of the zinc metalloprotease insulin-degrading enzyme in normal and malignant human breast: correlation with tissue insulin levelsRazvan T Radulescu
Clinical Research Unit, Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str 22, D 81675 Munchen, Germany
Int J Oncol 30:73-80. 2007..Our present report should also provide an experimental starting point towards exploring a potential role of IDE in the control of tumor progression...